Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Recruitment of first 26 patients of Phase 2A ACCENT Trial now complete
Biotech Daily | Dr Boreham's Crucible: Amplia Therapeutics
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Categories
Archive
Company News
Investor Newsletters
Videos
18 Dec 2023
Investor Newsletter - December 2023
Read More
20 Jul 2023
Investor Newsletter July 2023
Read More
1